Transgene Biotek (Small Cap) Share Target 2025, 2026 To 2035
|
Transgene Biotek Limited |
|||
|
Price: ₹4.51 (+1.35%) | ||
| 52 Week Low: ₹3.22 52 Week High: ₹10.84 |
|||
| Market Capital: 46.06 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Transgene Biotek Share Price Target For 2025
- 1.1.1: Transgene Biotek Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Transgene Biotek Share Price Target For 2026
- 1.2.1: Transgene Biotek Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Transgene Biotek Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Transgene Biotek Financial Performance
- 3.0.1: Is Transgene Biotek A Good Buy For Long Term?
Transgene Biotek, a Small Cap company has delivered 13.3% returns in 3-year.
To predict the Transgene Biotek's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Transgene Biotek Share Price Target For 2025
The line chart displays the monthly closing prices of Transgene Biotek with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Transgene Biotek shares in 2025, see the table below.
Transgene Biotek Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 5.61 (+24.39%) | Price Action: Chart |
| 2025 Target 2 | 5.51 (+22.17%) | Technical Indicator: MA200 |
| 2025 Target 1 | 5.39 (+19.51%) | Fibonacci Extension Level 23.60% |
| Current Price | 4.51 | Transgene Biotek's share price as of 26 Jun 2025 |
| Stop Loss 1 | 4.25 (-5.77%) | Price Action: 11 Feb 2025 Low |
| Stop Loss 2 | 4.2 (-6.88%) | Price Action: 18 Feb 2025 High |
| Stop Loss 3 | 4.15 (-7.99%) | Price Action: 14 Feb 2025 Low |
Short-Term Technical Outlook
Current Technical Position: Transgene Biotek is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹4.21 serves as the nearest technical reference point.
Historical Returns: 3-month: +19.39% | 6-month: -41.43% | 1-year: -54.29%
Transgene Biotek Share Price Target For 2026
The line chart displays the monthly closing prices of Transgene Biotek with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Transgene Biotek shares in 2026, see the table below.
Transgene Biotek Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 10.82 (+139.91%) | Price Action: Chart |
| 2026 Target 2 | 10.62 (+135.47%) | Price Action: Chart |
| 2026 Target 1 | 10.51 (+133.03%) | Fibonacci Extension Level 64.90% |
| Current Price | 4.51 | Transgene Biotek's share price as of 26 Jun 2025 |
| Stop Loss 1 | 3.05 (-32.38%) | Price Action: Chart |
| Stop Loss 2 | 3.02 (-33.04%) | Price Action: Chart |
| Stop Loss 3 | 2.97 (-34.15%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Transgene Biotek is currently trading near its 52-week low of ₹3.22, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -54.29% | 3-year: +13.31% | 5-year: -37.79%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Transgene Biotek Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹4.51 | ||
| 2025 | ₹4.67 | +3.54% | ₹4.74 |
| 2026 | ₹4.98 | +6.63% | ₹5.05 |
| 2027 | ₹5.37 | +7.83% | ₹5.45 |
| 2028 | ₹5.49 | +2.23% | ₹5.57 |
| 2029 | ₹5.86 | +6.73% | ₹5.95 |
| 2030 | ₹6.43 | +9.72% | ₹6.53 |
| 2031 | ₹6.87 | +6.84% | ₹6.97 |
| 2032 | ₹7.75 | +12.8% | ₹7.87 |
| 2033 | ₹8.50 | +9.67% | ₹8.63 |
| 2034 | ₹9.17 | +7.88% | ₹9.31 |
| 2035 | ₹9.08 | -0.98% | ₹9.22 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Transgene Biotek Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 46.06 Crore | Market valuation of Transgene Biotek's shares. |
| Revenue (TTM) | 5.5 Lakh | Total revenue generated by Transgene Biotek over the past twelve months. |
| Net Income (TTM) | -6 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -9,775.95% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -20.39% | Net income as a percentage of revenue, after all expenses. |
| Debt-to-Equity (D/E) Ratio |
1.22 | Company's total debt divided by total shareholder equity. |
| Total Debt | 13.56 Crore | Sum of Transgene Biotek's current & long-term financial obligations. |
Is Transgene Biotek A Good Buy For Long Term?
Due to its low market capitalization, negative profit margin, and significant debt, Transgene Biotek is not a recommended buy at present. Its recent negative returns and low revenue generation further support this view.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
